Picture of Synthaverse SA logo

SVE Synthaverse SA Share Price

0.000.00%
pl flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

Momentum

Relative Strength (%)
1m+26.29%
3m+7.25%
6m-14.86%
1yr-25.19%
Volume Change (%)
10d/3m+58.6%
Price vs... (%)
52w High-19.41%
50d MA+19.55%
200d MA+4.47%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)29.76
PEG Ratio (f)0.62
EPS Growth (f)91.33%
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value3.06
Price to Tang. Book3.07
Price to Free Cashflown/a
Price to Sales5.87
EV to EBITDA27.48

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital3.68%
Return on Equity4.36%
Operating Margin14.75%

Financial Summary

Year End 31st DecUnit201920202021202220232024E2025ECAGR / Avg
Total RevenuePLNm39.1140.1641.1550.3858.6163.4102.212.66%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%n/a+82.08-1.47+24.77-19.46+25.94+200n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Synthaverse SA EPS forecast chart

Profile Summary

Synthaverse SA formerly known as Biomed Lublin Wytwornia Surowic i Szczepionek SA is a Poland-based company operating in the Life Science industry, dealing primarily with the production of medicines. The Company focuses on the production of drugs in the field of immunotherapy. Synthaverse SA offers its services in the field such as: oncological immunotherapy, Immunotherapy in Serological Conflict, Passive immunotherapy in hepatitis B, Active anti-tuberculosis immunotherapy, Gynecology and Proctology, Probiotics, Laboratory reagents. The Company offers injection drugs, lyophilisates of active substances in sterile sealed vials, active substances and drugs based on surface and submerged biological culture, suppository forms of drugs. The Company supplies its products to 50 countries around the world.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
December 13th, 2010
Public Since
July 29th, 2011
No. of Employees
239
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
pl flag iconWarsaw Stock Exchange
Shares in Issue
70,260,410
Blurred out image of a map
Address
ul. Uniwersytecka 10, LUBLIN, 20-029
Web
https://synthaverse.pl/
Phone
+48 815338221
Auditors
UHY ECA Audyt Sp. Zoo SP. k.

SVE Share Price Performance

Upcoming Events for SVE

Similar to SVE

Picture of Bioceltix SA logo

Bioceltix SA

pl flag iconWarsaw Stock Exchange

Picture of Biogened SA logo

Biogened SA

pl flag iconWarsaw Stock Exchange

Picture of BioMaxima SA logo

BioMaxima SA

pl flag iconWarsaw Stock Exchange

Picture of Cannabis Poland SA logo

Cannabis Poland SA

pl flag iconWarsaw Stock Exchange

Picture of Celon Pharma SA logo

Celon Pharma SA

pl flag iconWarsaw Stock Exchange

FAQ